Skip NavigationSkip to Content

Biomedicinals from the phytosymbionts of marine invertebrates: A molecular approach

  1. Author:
    Dunlap, W. C.
    Battershill, C. N.
    Liptrot, C. H.
    Cobb, R. E.
    Bourne, D. G.
    Jaspars, M.
    Long, P. F.
    Newman, D. J.
  2. Author Address

    Australian Inst Marine Sci, Townsville, Qld 4810, Australia. Univ Aberdeen, Dept Chem, Aberdeen, Scotland. Univ London, Sch Pharm, London WC1N 1AX, England. NCI, Nat Prod Branch, Dev Therapeut Program, Frederick, MD 21701 USA.;Dunlap, WC, Australian Inst Marine Sci, PMB 3, Townsville, Qld 4810, Australia.;w.dunlap@aims.gov.au
    1. Year: 2007
    2. Date: Aug
  1. Journal: Methods
    1. 42
    2. 4
    3. Pages: 358-376
  2. Type of Article: Review
  3. ISSN: 1046-2023
  1. Abstract:

    Marine invertebrate animals such as sponges, gorgonians, tunicates and bryozoans are sources of biomedicinally relevant natural products, a small but growing number of which are advancing through clinical trials. Most metazoan and anthozoan species harbour commensal microorganisms that include prokaryotic bacteria, cyanobacteria (blue-green algae), eukaryotic microalgae, and fungi within host tissues where they reside as extra- and intra-cellular symbionts. In some sponges these associated microbes may constitute as much as 40% of the holobiont volume. There is now abundant evidence to suggest that a significant portion of the bioactive metabolites thought originally to be products of the source animal are often synthesized by their symbiotic microbiota. Several anti-cancer metabolites from marine sponges that have progressed to pre-clinical or clinical-trial phases, such as discodermolide, halichondrin B and bryostatin 1, are thought to be products derived from their microbiotic consortia. Freshwater and marine cyanobacteria are well recognised for producing numerous and structurally diverse bioactive and cytotoxic secondary metabolites suited to drug discovery. Sea sponges often contain dominant taxa-specific populations of cyanobacteria, and it is these phytosymbionts (= photosymbionts) that are considered to be the true biogenic source of a number of pharmacologically active polyketides and nonribosomally synthesized peptides produced within the sponge. Accordingly, new collections can be pre-screened in the field for the presence of phytobionts and, together with metagenomic screening using degenerate PCR primers to identify key polyketide synthase (PKS) and nonribosomal peptide synthetase (NRPS) genes, afford a biodiscovery rationale based on the therapeutic prospects of phytochemical selection. Additionally, new cloning and biosynthetic expression strategies may provide a sustainable method for the supply of new pharmaceuticals derived from the uncultured phytosymbionts of marine organisms. (C) 2007 Elsevier Inc. All rights reserved.

    See More

External Sources

  1. DOI: 10.1016/j.ymeth.2007.03.001
  2. WOS: 000247734000008

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel